These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
5. Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity. Abbeduto L; Berry-Kravis E; Sterling A; Sherman S; Edgin JO; McDuffie A; Hoffmann A; Hamilton D; Nelson M; Aschkenasy J; Thurman AJ J Neurodev Disord; 2020 Mar; 12(1):10. PubMed ID: 32204695 [TBL] [Abstract][Full Text] [Related]
6. Characterization of potential outcome measures for future clinical trials in fragile X syndrome. Berry-Kravis E; Sumis A; Kim OK; Lara R; Wuu J J Autism Dev Disord; 2008 Oct; 38(9):1751-7. PubMed ID: 18369716 [TBL] [Abstract][Full Text] [Related]
7. Disease-Targeted Treatment Translation in Fragile X Syndrome as a Model for Neurodevelopmental Disorders. Berry-Kravis E J Child Neurol; 2022 Oct; 37(10-11):797-812. PubMed ID: 35791522 [TBL] [Abstract][Full Text] [Related]
8. Vocabulary comprehension in adults with fragile X syndrome (FXS). Hoffmann A; Krause SE; Wuu J; Leurgans S; Guter SJ; Block SS; Salt J; Cook E; Maino DM; Berry-Kravis E J Neurodev Disord; 2019 Oct; 11(1):25. PubMed ID: 31619160 [TBL] [Abstract][Full Text] [Related]
9. Increased aperiodic gamma power in young boys with Fragile X Syndrome is associated with better language ability. Wilkinson CL; Nelson CA Mol Autism; 2021 Feb; 12(1):17. PubMed ID: 33632320 [TBL] [Abstract][Full Text] [Related]
10. A 'learning platform' approach to outcome measurement in fragile X syndrome: a preliminary psychometric study. Hall SS; Hammond JL; Hirt M; Reiss AL J Intellect Disabil Res; 2012 Oct; 56(10):947-60. PubMed ID: 22533667 [TBL] [Abstract][Full Text] [Related]
11. The challenges of clinical trials in fragile X syndrome. Jacquemont S; Berry-Kravis E; Hagerman R; von Raison F; Gasparini F; Apostol G; Ufer M; Des Portes V; Gomez-Mancilla B Psychopharmacology (Berl); 2014 Mar; 231(6):1237-50. PubMed ID: 24173622 [TBL] [Abstract][Full Text] [Related]
12. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. Berry-Kravis E; Krause SE; Block SS; Guter S; Wuu J; Leurgans S; Decle P; Potanos K; Cook E; Salt J; Maino D; Weinberg D; Lara R; Jardini T; Cogswell J; Johnson SA; Hagerman R J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):525-40. PubMed ID: 17069542 [TBL] [Abstract][Full Text] [Related]
13. Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment. Hessl D; Berry-Kravis E; Cordeiro L; Yuhas J; Ornitz EM; Campbell A; Chruscinski E; Hervey C; Long JM; Hagerman RJ Am J Med Genet B Neuropsychiatr Genet; 2009 Jun; 150B(4):545-53. PubMed ID: 18785205 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. Berry-Kravis EM; Harnett MD; Reines SA; Reese MA; Ethridge LE; Outterson AH; Michalak C; Furman J; Gurney ME Nat Med; 2021 May; 27(5):862-870. PubMed ID: 33927413 [TBL] [Abstract][Full Text] [Related]
15. Social cognition in adolescent girls with fragile x syndrome. Turkstra LS; Abbeduto L; Meulenbroek P Am J Intellect Dev Disabil; 2014 Jul; 119(4):319-39. PubMed ID: 25007297 [TBL] [Abstract][Full Text] [Related]
17. Cognitive training for children and adolescents with fragile X syndrome: a randomized controlled trial of Cogmed. Hessl D; Schweitzer JB; Nguyen DV; McLennan YA; Johnston C; Shickman R; Chen Y J Neurodev Disord; 2019 Apr; 11(1):4. PubMed ID: 30982467 [TBL] [Abstract][Full Text] [Related]
18. Emerging pharmacologic treatment options for fragile X syndrome. Schaefer TL; Davenport MH; Erickson CA Appl Clin Genet; 2015; 8():75-93. PubMed ID: 25897255 [TBL] [Abstract][Full Text] [Related]
19. Effects of AFQ056 on language learning in fragile X syndrome. Berry-Kravis E; Abbeduto L; Hagerman R; Coffey CS; Cudkowicz M; Erickson CA; McDuffie A; Hessl D; Ethridge L; Tassone F; Kaufmann WE; Friedmann K; Bullard L; Hoffmann A; Veenstra-VanderWeele J; Staley K; Klements D; Moshinsky M; Harkey B; Long J; Fedler J; Klingner E; Ecklund D; Costigan M; Huff T; Pearson B; J Clin Invest; 2023 Aug; 134(5):. PubMed ID: 37651202 [TBL] [Abstract][Full Text] [Related]
20. State-of-the-art therapies for fragile X syndrome. Protic D; Hagerman R Dev Med Child Neurol; 2024 Jul; 66(7):863-871. PubMed ID: 38385885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]